Email this article Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem
- Authors: Alekseev B.Y.1,2
-
Affiliations:
- N.А. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
- 4 Bldg, 51, 3erd Parkovaya St., Moscow, 105425, Russia
- Issue: Vol 11, No 3 (2015)
- Pages: 108-116
- Section: REVIEW
- Published: 30.09.2015
- URL: https://oncourology.abvpress.ru/oncur/article/view/497
- DOI: https://doi.org/10.17650/1726-9776-2015-11-3-108-116
- ID: 497
Cite item
Full Text
Abstract
The paper reviews the current possibilities of cytostatic chemotherapy in patients with metastatic prostate cancer. It gives the data of studies dealing with the early use of docetaxel in patents with hormone-susceptible tumors and analyzes approaches to sequential therapy with docetaxel, cabazitaxel, and antiandrogens (abiraterone, enzalutamide) in patients with castration-refractory prostate cancer. Assessment of the prognostic role of different clinical and biological factors could provide an algorithm for the choice of first- and second-line therapy in patients with castration resistance.
About the authors
B. Ya. Alekseev
N.А. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical ResearchRadiological Centre of the Ministry of Health of the Russian Federation; 4 Bldg, 51, 3erd Parkovaya St., Moscow, 105425, Russia
Author for correspondence.
Email: byalekseev@mail.ru
Russian Federation
References
Supplementary files
